QLINEA Share Price Performance
SEK 0
-1030.00 (-100.00%)
Price SEK 0
Fair ValueSEK 80.00
Share Pricen/a
Q-linea AB (publ) Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
QLINEA Community Narratives
AN
Fair Value SEK 80 74.0% undervalued intrinsic discount
Slow Integration And Competition Will Hinder Revenue With Emerging Promise
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value SEK 53 60.7% undervalued intrinsic discount
Overvaluation Will Persist As Italy And US Markets Evolve
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Overvaluation Will Persist As Italy And US Markets Evolve
Key Takeaways Growth and profitability assumptions rely on optimistic adoption rates and premium pricing, both threatened by slow expansions, budget constraints, and rising competition. High R&D costs, cash burn, and buyer bargaining power risk limiting future margin expansion, increasing dilution, and depressing earnings expectations.Read more
29
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
SEK 53
60.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
208.34% p.a.
Profit Margin
8.07%
Future PE
17.38x
Price in 2028
SEK 31.2
Slow Integration And Competition Will Hinder Revenue With Emerging Promise
Key Takeaways Growth drivers include increased clinical adoption and market mandates, but long sales cycles, regulatory delays, and volatile demand hinder consistent revenue and market share gains. Intensifying competition, escalating R&D costs, and budget constraints threaten profitability, recurring revenue streams, and the effective utilization of Q-linea's installed platforms.Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 80
74.0% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
237% p.a.
Profit Margin
8.7%
Future PE
25.14x
Price in 2028
SEK 47.02
Trending Discussion
Recently Updated Narratives
AN
QLINEA: Expanded Sepsis Panel Approval Will Drive Strong Future Upside
Fair Value: SEK 53 60.7% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Slow Integration And Competition Will Hinder Revenue With Emerging Promise
Fair Value: SEK 80 74.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Q-linea AB (publ) Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 06, 2026
- -9.94
- -64.38%
- -1,755.24%
- 46.3%
About QLINEA
- Founded
- 2007
- Employees
- 83
- CEO
- WebsiteView website
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture unit for incubating and detecting growth in blood bottles. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.
